XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.2.u1
Stockholders' equity (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Mar. 11, 2024
USD ($)
$ / shares
shares
Nov. 12, 2020
USD ($)
Feb. 28, 2023
USD ($)
$ / shares
shares
Jun. 30, 2024
USD ($)
$ / shares
shares
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Vote
$ / shares
shares
Jun. 30, 2023
USD ($)
shares
Mar. 31, 2024
$ / shares
shares
Jan. 26, 2024
USD ($)
Dec. 31, 2023
$ / shares
shares
Common stock                    
Stock, shares authorized | shares       440,000,000   440,000,000        
Common stock, shares authorized | shares       400,000,000   400,000,000   400,000,000   400,000,000
Common stock, par value (in dollars per share) | $ / shares       $ 0.001   $ 0.001   $ 0.001   $ 0.001
Preferred stock, shares authorized | shares       40,000,000   40,000,000        
Preferred stock, par value (in dollars per share) | $ / shares       $ 0.001   $ 0.001        
Common stock issuable upon conversion (in shares) | shares       28,112   28,112        
Number of voting rights per common share | Vote           1        
Stock based compensation expense       $ 128,488 $ 269,323 $ 214,318 $ 285,567      
Shelf Registration Statement                    
Proceeds from issuance of common stock           15,999,598 5,788,918      
Common stock issuance costs           1,310,953 $ 648,928      
March 2024 Private Placement                    
Warrant exercises           $ 0        
Series A Convertible Preferred Stock                    
Common stock                    
Convertible preferred stock, shares outstanding | shares       56,227   56,227       56,227
March 2024 Private Placement | Purchasers | Securities purchase agreement                    
Shelf Registration Statement                    
Shares issued | shares 1,687,712                  
Common stock issuance costs $ 1,300,000                  
March 2024 Private Placement                    
Offering price per share | $ / shares $ 7.29                  
Common stock with an exercise price | $ / shares $ 0.001                  
Percentage of outstanding shares 4.99%                  
Proceeds from sale of common stock in a private placement $ 16,000,000.0                  
Expected gross proceeds from potential future warrants cash exercise $ 18,000,000.0                  
March 2024 Private Placement | Purchasers | Securities purchase agreement | At the election of holder                    
March 2024 Private Placement                    
Percentage of outstanding shares 9.99%                  
March 2024 Private Placement | Purchasers | Securities purchase agreement | Pre-funded Warrants                    
March 2024 Private Placement                    
Offering price per share | $ / shares $ 7.289                  
Warrants to purchase of shares | shares 507,076                  
March 2024 Private Placement | Purchasers | Securities purchase agreement | Tranche A Warrants (Pre-funded Warrants Exercise Price 7.29 Per Share)                    
March 2024 Private Placement                    
Warrants to purchase of shares | shares 1,097,394                  
Common stock with an exercise price | $ / shares $ 7.29                  
Stock issuance anniversary period 3 years                  
Number of days after announcement of Phase 2 dose for ATRN-119 30 days                  
Volume weighted average price | $ / shares $ 14.58                  
Number of consecutive trading days 30 days                  
March 2024 Private Placement | Purchasers | Securities purchase agreement | Tranche B Warrants (Pre-funded Warrants Exercise Price 9.1125 Per Share)                    
March 2024 Private Placement                    
Common stock with an exercise price | $ / shares $ 9.1125                  
Stock issuance anniversary period 5 years                  
Number of days after announcement of Phase 2 dose for ATRN-119 30 days                  
Volume weighted average price | $ / shares $ 18.225                  
2020 Shelf Registration Statement                    
Shelf Registration Statement                    
Maximum amount to be issued under universal shelf registration statement   $ 350,000,000.0                
2020 Shelf Registration Statement | Common Stock                    
Shelf Registration Statement                    
Shares issued | shares     1,050,000              
Issue price per share | $ / shares     $ 5.25              
Proceeds from issuance of common stock     $ 4,900,000              
Common stock issuance costs     $ 600,000              
ATM offering                    
Common stock                    
Commission payable as a percentage of gross proceeds from sale of common stock under ATM offering   3.00%                
Shelf Registration Statement                    
Maximum amount to be issued under at-the-market offering program   $ 14,744,728                
Shares issued | shares             26,302      
Proceeds from issuance of common shares             $ 300,000      
Common stock issuance costs             $ 8,000      
2024 Shelf Registration Statement                    
Shelf Registration Statement                    
Maximum amount to be issued under universal shelf registration statement                 $ 150,000,000  
Maximum amount to be issued under at-the-market offering program                 1,000,000  
Maximum amount to be issued under at-the-market offering program, supplement                 2,000,000  
2024 ATM offering | HCW                    
Shelf Registration Statement                    
Maximum amount to be issued under at-the-market offering program                 $ 2,000,000